Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial.

Bruna R, Benedetti F, Boccomini C, Patti C, Barbui AM, Pulsoni A, Musso M, Liberati AM, Gini G, Castellino C, Rossini F, Ciceri F, Rota-Scalabrini D, Stelitano C, Di Raimondo F, Tucci A, Devizzi L, Zoli V, Zallio F, Narni F, Dondi A, Parvis G, Semenzato G, Lanza F, Perrone T, Angrilli F, Billio A, Gueli A, Mantoan B, Rambaldi A, Gianni AM, Corradini P, Passera R, Ladetto M, Tarella C.

Haematologica. 2019 Nov;104(11):2241-2248. doi: 10.3324/haematol.2018.209932. Epub 2019 Apr 11.

2.

Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience.

Marangon M, Stefoni V, Castellino A, Visco C, Tani M, Cox MC, Marasca R, Tecchio C, Devizzi L, Monaco F, Romano A, Rusconi C, Rigacci L, Castellino C, Gaudio F, Argnani L, Zinzani PL.

Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):e321-e323. doi: 10.1016/j.clml.2019.03.020. Epub 2019 Mar 29. No abstract available.

PMID:
31080169
3.

Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice.

Broccoli A, Casadei B, Chiappella A, Visco C, Tani M, Cascavilla N, Conconi A, Balzarotti M, Cox MC, Marino D, Goldaniga MC, Marasca R, Tecchio C, Patti C, Musuraca G, Devizzi L, Monaco F, Romano A, Fama A, Zancanella M, Paolini R, Rigacci L, Castellino C, Gaudio F, Argnani L, Zinzani PL.

Oncologist. 2019 Sep;24(9):1246-1252. doi: 10.1634/theoncologist.2018-0603. Epub 2019 Apr 2.

PMID:
30940746
4.

Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma.

Dodero A, Guidetti A, Tucci A, Barretta F, Novo M, Devizzi L, Re A, Passi A, Pellegrinelli A, Pruneri G, Miceli R, Testi A, Pennisi M, Di Chio MC, Matteucci P, Carniti C, Facchetti F, Rossi G, Corradini P.

Leukemia. 2019 Apr;33(4):1047-1051. doi: 10.1038/s41375-018-0320-9. Epub 2019 Jan 10. No abstract available.

5.

Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.

Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJM, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Moreau A, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C.

J Clin Oncol. 2017 Jun 10;35(17):1905-1912. doi: 10.1200/JCO.2016.70.6994. Epub 2017 Mar 29. Erratum in: J Clin Oncol. 2017 Jul 10;35(20):2342.

PMID:
28355112
6.

High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression.

Maura F, Guidetti A, Pellegrinelli A, Dodero A, Pennisi M, Caprioli C, Testi A, Farina L, Bolli N, Devizzi LF, Cabras A, Corradini P.

Blood Cancer J. 2017 Mar 17;7(3):e544. doi: 10.1038/bcj.2017.25. No abstract available.

7.

High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression.

Maura F, Guidetti A, Pellegrinelli A, Dodero A, Pennisi M, Caprioli C, Testi A, Farina L, Bolli N, Devizzi LF, Cabras A, Corradini P.

Blood Cancer J. 2016 Nov 4;6(11):e491. doi: 10.1038/bcj.2016.99. No abstract available. Erratum in: Blood Cancer J. 2017 Mar 17;7(3):e544.

8.

The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study.

Zinzani PL, Rigacci L, Cox MC, Devizzi L, Fabbri A, Zaja F, Di Rocco A, Rossi G, Storti S, Fattori PP, Argnani L, Vitolo U.

Leuk Lymphoma. 2017 Jan;58(1):226-229. Epub 2016 Jun 2. No abstract available.

PMID:
27252040
9.

Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.

Ruella M, Filippi AR, Bruna R, Di Russo A, Magni M, Caracciolo D, Passera R, Matteucci P, Di Nicola M, Corradini P, Parvis G, Gini G, Olivieri A, Ladetto M, Ricardi U, Tarella C, Devizzi L.

Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):783-91. doi: 10.1016/j.ijrobp.2015.12.019. Epub 2015 Dec 17.

PMID:
26972651
10.

Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice.

Zinzani PL, Rigacci L, Cox MC, Devizzi L, Fabbri A, Zaccaria A, Zaja F, Di Rocco A, Rossi G, Storti S, Fattori PP, Argnani L, Tura S, Vitolo U.

Leuk Lymphoma. 2015 Jun;56(6):1671-6. doi: 10.3109/10428194.2014.964702. Epub 2014 Nov 19.

PMID:
25241999
11.

Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group.

Conconi A, Raderer M, Franceschetti S, Devizzi L, Ferreri AJ, Magagnoli M, Arcaini L, Zinzani PL, Martinelli G, Vitolo U, Kiesewetter B, Porro E, Stathis A, Gaidano G, Cavalli F, Zucca E.

Br J Haematol. 2014 Jul;166(1):69-76. doi: 10.1111/bjh.12845. Epub 2014 Mar 27.

PMID:
24673512
12.

Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis.

Magni M, Di Nicola M, Patti C, Scimè R, Mulè A, Rambaldi A, Intermesoli T, Viero P, Tarella C, Gueli A, Bergui L, Trentin L, Barzan A, Benedetti F, Ambrosetti A, Di Raimondo F, Chiarenza A, Parvis G, Billio A, Attolico I, Olivieri A, Montanari M, Carlo-Stella C, Matteucci P, Devizzi L, Guidetti A, Viviani S, Valagussa P, Gianni AM.

Bone Marrow Transplant. 2014 Apr;49(4):485-91. doi: 10.1038/bmt.2013.214. Epub 2014 Jan 20.

PMID:
24442244
13.

The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy.

Rambaldi A, Boschini C, Gritti G, Delaini F, Oldani E, Rossi A, Barbui AM, Caracciolo D, Ladetto M, Gueli A, De Crescenzo A, Passera R, Devizzi L, Patti C, Gianni AM, Tarella C.

Am J Hematol. 2013 Dec;88(12):1062-7. doi: 10.1002/ajh.23566. Epub 2013 Sep 30.

14.

Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM.

Devizzi L, Guidetti A, Seregni E, Passera R, Maccauro M, Magni M, Testi A, Di Nicola M, Tarella C, Matteucci P, Viviani S, Ruella M, Carlo-Stella C, Chiesa C, Cox MC, Bombardieri E, Gianni AM.

J Clin Oncol. 2013 Aug 10;31(23):2974-6. doi: 10.1200/JCO.2013.50.2922. Epub 2013 Jul 15. No abstract available.

15.

Successful second autologous engraftment after long duration storage of hematopoietic stem cells.

Longoni P, Milanesi M, Di Nicola M, Devizzi L, Carrabba M, Arienti F, Ravagnani F, Tarella C, Montefusco V, Gianni A, Corradini P, Magni M.

Bone Marrow Transplant. 2013 Nov;48(11):1480-1. doi: 10.1038/bmt.2013.81. Epub 2013 May 27. No abstract available.

PMID:
23708707
16.

Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial.

Ferreri AJ, Govi S, Raderer M, Mulè A, Andriani A, Caracciolo D, Devizzi L, Ilariucci F, Luminari S, Viale E, Müllauer L, Dell'Oro S, Arcidiacono PG, Ponzoni M, Patti C.

Blood. 2012 Nov 1;120(18):3858-60. doi: 10.1182/blood-2012-06-438424. No abstract available.

PMID:
23118214
17.

Detection of minimal residual disease in hematopoietic progenitor cell harvests: lack of predictive value of peripheral blood and bone marrow analysis in mantle cell and indolent lymphoma.

Magni M, Di Nicola M, Carlo-Stella C, Matteucci P, Devizzi L, Guidetti A, Ravagnani F, Gianni AM.

Am J Blood Res. 2012;2(2):105-12. Epub 2012 Apr 15.

18.

Phase II study of sorafenib in patients with relapsed or refractory lymphoma.

Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Pierdominici M, Barbati C, Mortarini R, Devizzi L, Matteucci P, Marchianò A, Lanocita R, Farina L, Dodero A, Tarella C, Di Nicola M, Corradini P, Anichini A, Gianni AM.

Br J Haematol. 2012 Jul;158(1):108-19. doi: 10.1111/j.1365-2141.2012.09139.x. Epub 2012 May 10.

PMID:
22571717
19.

Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia.

Guidetti A, Carlo-Stella C, Ruella M, Miceli R, Devizzi L, Locatelli SL, Giacomini A, Testi A, Buttiglieri S, Risso A, Mariani L, Di Nicola M, Passera R, Tarella C, Gianni AM.

Cancer. 2011 Nov 15;117(22):5074-84. doi: 10.1002/cncr.26182. Epub 2011 May 12.

20.

CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11).

Mian M, Marcheselli L, Luminari S, Federico M, Cantonetti M, Sarris AH, Rossi A, Rambaldi A, Frontani M, Devizzi L, Gianni AM, Busetto M, Berti E, Martinelli G, Tsang RW, Ferreri AJ, Pinotti G, Pogliani E, Zucca E, Cortelazzo S.

Ann Hematol. 2011 Apr;90(4):401-8. doi: 10.1007/s00277-010-1083-1. Epub 2010 Sep 25.

PMID:
20872000
21.

Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).

Conconi A, Martinelli G, Lopez-Guillermo A, Zinzani PL, Ferreri AJ, Rigacci L, Devizzi L, Vitolo U, Luminari S, Cavalli F, Zucca E; International Extranodal Lymphoma Study Group (IELSG).

Ann Oncol. 2011 Mar;22(3):689-95. doi: 10.1093/annonc/mdq416. Epub 2010 Sep 1.

PMID:
20810546
22.

MALT lymphoma and Kaposi sarcoma in an HIV-negative patient.

Mirabile A, Devizzi L, Gianni AM, Cabras A, Carbone A.

Am J Hematol. 2010 Oct;85(10):815-7. doi: 10.1002/ajh.21802.

23.

Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience.

Viviani S, Di Nicola M, Bonfante V, Di Stasi A, Carlo-Stella C, Matteucci P, Magni M, Devizzi L, Valagussa P, Gianni AM.

Leuk Lymphoma. 2010 Jul;51(7):1251-9. doi: 10.3109/10428194.2010.486090.

PMID:
20528244
24.

Efficacy and safety of high-dose chemotherapy with in vivo purged auto-SCT in relapsed follicular lymphoma: long-term follow-up.

Magni M, Di Nicola M, Carlo-Stella C, Devizzi L, Guidetti A, Matteucci P, Gianni AM.

Bone Marrow Transplant. 2010 Jun;45(6):1119-20. doi: 10.1038/bmt.2009.294. Epub 2009 Oct 12. No abstract available.

PMID:
19820728
25.

Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin).

Chiesa C, Botta F, Coliva A, Maccauro M, Devizzi L, Guidetti A, Carlo-Stella C, Seregni E, Gianni MA, Bombardieri E.

Eur J Nucl Med Mol Imaging. 2009 Nov;36(11):1745-57. doi: 10.1007/s00259-009-1141-x. Epub 2009 May 20.

PMID:
19455328
26.

Radioimmunotherapy and secondary leukemia: a case report.

Magni M, Di Nicola M, Testi A, Cabras A, Devizzi L, Guidetti A, Matteucci P, Viviani S, Bonfante V, Carniti C, Ricca I, Carbone A, Carlo-Stella C, Gianni AM.

Leuk Res. 2010 Jan;34(1):e1-4. doi: 10.1016/j.leukres.2009.04.028. Epub 2009 May 15.

PMID:
19446876
27.

High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen.

Magni M, Di Nicola M, Carlo-Stella C, Matteucci P, Devizzi L, Tarella C, Benedetti F, Martelli M, Patti C, Parvis G, Rambaldi A, Barbui T, Gianni AM.

Bone Marrow Transplant. 2009 Mar;43(6):509-11. doi: 10.1038/bmt.2008.349. Epub 2008 Oct 27. No abstract available.

PMID:
18955979
28.

High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation.

Devizzi L, Guidetti A, Tarella C, Magni M, Matteucci P, Seregni E, Chiesa C, Bombardieri E, Di Nicola M, Carlo-Stella C, Gianni AM.

J Clin Oncol. 2008 Nov 10;26(32):5175-82. doi: 10.1200/JCO.2008.16.8294. Epub 2008 Oct 14.

PMID:
18854569
29.

Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study.

Di Nicola M, Zappasodi R, Carlo-Stella C, Mortarini R, Pupa SM, Magni M, Devizzi L, Matteucci P, Baldassari P, Ravagnani F, Cabras A, Anichini A, Gianni AM.

Blood. 2009 Jan 1;113(1):18-27. doi: 10.1182/blood-2008-06-165654. Epub 2008 Sep 22.

PMID:
18809757
30.

Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group.

Ryan G, Martinelli G, Kuper-Hommel M, Tsang R, Pruneri G, Yuen K, Roos D, Lennard A, Devizzi L, Crabb S, Hossfeld D, Pratt G, Dell'Olio M, Choo SP, Bociek RG, Radford J, Lade S, Gianni AM, Zucca E, Cavalli F, Seymour JF; International Extranodal Lymphoma Study Group.

Ann Oncol. 2008 Feb;19(2):233-41. Epub 2007 Oct 11.

PMID:
17932394
31.

Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results.

Chiesa C, Botta F, Di Betta E, Coliva A, Maccauro M, Aliberti G, Bavusi S, Devizzi L, Guidetti A, Seregni E, Gianni AM, Bombardieri E.

Cancer Biother Radiopharm. 2007 Feb;22(1):113-20.

PMID:
17627419
32.

Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi).

Tarella C, Zanni M, Di Nicola M, Patti C, Calvi R, Pescarollo A, Zoli V, Fornari A, Novero D, Cabras A, Stella M, Comino A, Remotti D, Ponzoni M, Caracciolo D, Ladetto M, Magni M, Devizzi L, Rosato R, Boccadoro M, Bregni M, Corradini P, Gallamini A, Majolino I, Mirto S, Gianni AM; Gruppo Italiano Terapie Innovative nei Linfomi.

Leukemia. 2007 Aug;21(8):1802-11. Epub 2007 Jun 7.

PMID:
17554382
33.

High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults.

Di Nicola M, Carlo-Stella C, Mariotti J, Devizzi L, Massimino M, Cabras A, Magni M, Matteucci P, Guidetti A, Gandola L, Gianni AM.

Br J Haematol. 2004 Sep;126(6):815-20.

PMID:
15352985
34.

Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study.

Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, Morabito F, Martelli M, Brusamolino E, Iannitto E, Zaja F, Cortelazzo S, Rigacci L, Devizzi L, Todeschini G, Santini G, Brugiatelli M, Federico M; Intergruppo Italiano Linfomi.

Blood. 2004 Apr 1;103(7):2474-9. Epub 2003 Nov 26.

PMID:
14645001
35.

Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type.

Conconi A, Martinelli G, Thiéblemont C, Ferreri AJ, Devizzi L, Peccatori F, Ponzoni M, Pedrinis E, Dell'Oro S, Pruneri G, Filipazzi V, Dietrich PY, Gianni AM, Coiffier B, Cavalli F, Zucca E.

Blood. 2003 Oct 15;102(8):2741-5. Epub 2003 Jul 3.

PMID:
12842999
36.

Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience.

Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, Devizzi L, Berger F, Ponzoni M, Borisch B, Tinguely M, Cerati M, Milani M, Orvieto E, Sanchez J, Chevreau C, Dell'Oro S, Zucca E, Cavalli F.

J Clin Oncol. 2003 Jan 15;21(2):266-72.

PMID:
12525518
37.

Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients.

Zinzani PL, Martelli M, Bertini M, Gianni AM, Devizzi L, Federico M, Pangalis G, Michels J, Zucca E, Cantonetti M, Cortelazzo S, Wotherspoon A, Ferreri AJ, Zaja F, Lauria F, De Renzo A, Liberati MA, Falini B, Balzarotti M, Calderoni A, Zaccaria A, Gentilini P, Fattori PP, Pavone E, Angelopoulou MK, Alinari L, Brugiatelli M, Di Renzo N, Bonifazi F, Pileri SA, Cavalli F; International Extranodal Lymphoma Study Group (IELSG).

Haematologica. 2002 Dec;87(12):1258-64.

38.

Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.

Zucca E, Conconi A, Pedrinis E, Cortelazzo S, Motta T, Gospodarowicz MK, Patterson BJ, Ferreri AJ, Ponzoni M, Devizzi L, Giardini R, Pinotti G, Capella C, Zinzani PL, Pileri S, López-Guillermo A, Campo E, Ambrosetti A, Baldini L, Cavalli F; International Extranodal Lymphoma Study Group.

Blood. 2003 Apr 1;101(7):2489-95. Epub 2002 Nov 27.

PMID:
12456507
39.

The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies.

Cortelazzo S, Rossi A, Oldani E, Motta T, Giardini R, Zinzani PL, Zucca E, Gomez H, Ferreri AJ, Pinotti G, Chini C, Devizzi L, Gianni AM, Cavalli F, Barbui T; International Extranodal Lymphoma Study Group (IELSG).

Br J Haematol. 2002 Jul;118(1):218-28.

PMID:
12100151
40.

High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease.

Bonfante V, Viviani S, Devizzi L, Di Russo A, Di Nicola M, Magni M, Matteucci P, Grisanti S, Valagussa P, Bonadonna G, Gianni AM.

Eur J Haematol Suppl. 2001 Jul;64:51-5.

PMID:
11486403
41.

Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion.

Magni M, Di Nicola M, Devizzi L, Matteucci P, Lombardi F, Gandola L, Ravagnani F, Giardini R, Dastoli G, Tarella C, Pileri A, Bonadonna G, Gianni AM.

Blood. 2000 Aug 1;96(3):864-9.

PMID:
10910898
42.

Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study.

Santoro A, Bredenfeld H, Devizzi L, Tesch H, Bonfante V, Viviani S, Fiedler F, Parra HS, Benoehr C, Pacini M, Bonadonna G, Diehl V.

J Clin Oncol. 2000 Jul;18(13):2615-9.

PMID:
10893294
43.

Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease.

Viviani S, Bonfante V, Santoro A, Zanini M, Devizzi L, Di Russo AD, Soncini F, Villani F, Ragni G, Valagussa P, Bonadonna G.

Cancer J Sci Am. 1999 Sep-Oct;5(5):275-82.

PMID:
10526668
44.

Changing biodistribution of gallium during G-CSF treatment in non- Hodgkin's disease.

Maffioli LS, Castellani MR, Bombardieri E, Devizzi L, Draisma A, Pauwels E.

Eur J Nucl Med. 1999 Jan;26(1):68-9. No abstract available.

PMID:
10048953
45.

Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease.

Bonfante V, Viviani S, Santoro A, Devizzi L, Di Russo A, Zanini M, Soncini F, Soto Parra H, Valagussa P, Bonadonna G.

Br J Haematol. 1998 Nov;103(2):533-5.

PMID:
9827930
46.

Gallium-67 scintigraphy evaluation of therapy in non-Hodgkin's lymphoma.

Gasparini M, Bombardieri E, Castellani M, Tondini C, Maffioli L, Devizzi L, Gerundini P.

J Nucl Med. 1998 Sep;39(9):1586-90.

47.

Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications.

Viviani S, Camerini E, Bonfante V, Santoro A, Balzarotti M, Fornier M, Devizzi L, Verderio P, Valagussa P, Bonadonna G.

Br J Cancer. 1998 Mar;77(6):992-7.

48.

Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD.

Bonfante V, Santoro A, Viviani S, Devizzi L, Balzarotti M, Soncini F, Zanini M, Valagussa P, Bonadonna G.

J Clin Oncol. 1997 Feb;15(2):528-34.

PMID:
9053474
49.

Comparison of gallium scan, computed tomography, and magnetic resonance in patients with mediastinal Hodgkin's disease.

Devizzi L, Maffioli L, Bonfante V, Viviani S, Balzarini L, Gasparini M, Valagussa P, Bombardieri E, Santoro A, Bonadonna G.

Ann Oncol. 1997;8 Suppl 1:53-6.

PMID:
9187430
50.

Lack of carboplatin activity in malignant lymphomas.

Balzarotti M, Tondini C, Bonfante V, Devizzi L, Viviani S, Fornier M, Santoro A.

Eur J Cancer. 1996 Dec;32A(13):2370-1. No abstract available.

PMID:
9038628

Supplemental Content

Loading ...
Support Center